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Introduction {#acn3649-sec-0005}
============

Limb‐girdle muscular dystrophies (LGMD) are a group of heterogeneous genetic disorders involving proximal muscle weakness with autosomal‐recessive or‐dominant inheritance. LGMD have more than 30 different subtypes linked to specific gene loci, which manifest in very overlapping and heterogeneous phenotypes.[1](#acn3649-bib-0001){ref-type="ref"}, [2](#acn3649-bib-0002){ref-type="ref"}, [3](#acn3649-bib-0003){ref-type="ref"} This is likely the result of a tight link between associated muscle proteins within the sarcomere‐sarcolemma‐sarcoplasm‐extracellular‐matrix network ([Fig. S1](#acn3649-sup-0001){ref-type="supplementary-material"}). The dominant forms (LGMD1A to LGMD1G) are less common than the recessive forms, representing fewer than 10% of LGMD cases.[1](#acn3649-bib-0001){ref-type="ref"}, [4](#acn3649-bib-0004){ref-type="ref"} Defects in a wide variety of muscle‐related genes, including ones associated with severe congenital muscular dystrophy, are responsible for the 23 recessive forms (LGMD2A to LGMD2W).[1](#acn3649-bib-0001){ref-type="ref"}, [4](#acn3649-bib-0004){ref-type="ref"}, [5](#acn3649-bib-0005){ref-type="ref"}, [6](#acn3649-bib-0006){ref-type="ref"} Even though each of the individual LGMD subtypes is relatively rare, they are estimated to affect 1 in 14,500 to 1 in 123,000 individuals causing them to collectively affect many people (60,000 to 500,000 individuals) worldwide and is one of the most common muscular dystrophies.[3](#acn3649-bib-0003){ref-type="ref"}

The substantial overlap and variability among each LGMD subtype in the age of onset, severity, and affected muscle groups, and the fact that cost of gene testing was previously unaffordable for patients, make definitive diagnosis highly elusive.[7](#acn3649-bib-0007){ref-type="ref"} The lack of establishing a genotype prior to targeted therapeutic approaches obstructs recruitment of LGMD patients to available clinical trials.[8](#acn3649-bib-0008){ref-type="ref"}, [9](#acn3649-bib-0009){ref-type="ref"}, [10](#acn3649-bib-0010){ref-type="ref"}, [11](#acn3649-bib-0011){ref-type="ref"} Only five of the 12 LGMD trials are LGMD‐subtype‐specific.[8](#acn3649-bib-0008){ref-type="ref"} Recently, the FDA approved Phases 1b and 2 of clinical trial NCT02579239 for (Resolaris^™)^ an orphan drug developed by aTyR Pharma for treatment of LGMD2B based on targeting the immune component of the disease subtype. No global or other subtype‐specific approved therapy is available yet. In this genomic era, establishment of such therapies is greatly facilitated by a comprehensive diagnostic approach including clinical‐pathological evaluation, and cost‐effective parallel testing of several genes using next‐generation sequencing (NGS) so that faster diagnosis can be achieved to help patients to avail such personalized therapies, management, or to be recruited for specific clinical trials.

Several studies reported the use of exomes or gene panels in small LGMD cohorts elsewhere.[12](#acn3649-bib-0012){ref-type="ref"}, [13](#acn3649-bib-0013){ref-type="ref"}, [14](#acn3649-bib-0014){ref-type="ref"}, [15](#acn3649-bib-0015){ref-type="ref"}, [16](#acn3649-bib-0016){ref-type="ref"} We previously showed that for NMDs such as LGMD, comprehensive gene‐panel testing has a higher clinical yield (46%) than single‐gene testing (15%) or has about 18% higher detection rate of causative pathogenic variants than exome sequencing.[17](#acn3649-bib-0017){ref-type="ref"}

Previously, multiple targeted disease‐specific panel NGS efforts including that of LGMD for molecular diagnostics were performed.[12](#acn3649-bib-0012){ref-type="ref"}, [18](#acn3649-bib-0018){ref-type="ref"}, [19](#acn3649-bib-0019){ref-type="ref"}, [20](#acn3649-bib-0020){ref-type="ref"}, [21](#acn3649-bib-0021){ref-type="ref"}, [22](#acn3649-bib-0022){ref-type="ref"}, [23](#acn3649-bib-0023){ref-type="ref"}, [24](#acn3649-bib-0024){ref-type="ref"} But to our knowledge, this study uniquely surpasses them by recruiting a very large number (4656) of patients clinically suspected of a specific disorder (LGMDs) in the USA irrespective of ethnicities. We aimed to provide complete molecular diagnosis to this large group of clinically characterized LGMD patients. We also aimed to understand the respective prevalence, the gene‐variant spectrum of LGMD subtypes across the USA, and novel disease mechanisms leading to unusual clinical presentation and progression of LGMD that can broaden understanding of disease inheritance and apply to other heterogeneous inherited diseases.

Methods {#acn3649-sec-0006}
=======

Patient enrollment {#acn3649-sec-0007}
------------------

The Muscular Dystrophy Association (MDA) and Jain Foundation jointly launched large‐scale LGMD molecular diagnostic testing through Emory Genetics Laboratory (EGL). The study included 4656 individuals not reported previously who underwent molecular testing from June 2015 to June 2017. The study protocols have received prior approval by the Emory University Institutional Review Board, and that informed consent was obtained from each subject for genetic testing using the targeted LGMD gene‐panel NGS and for collecting and using their clinical data in this study.

The inclusion criteria for this study were clinical suspicion of LGMD based on clinical data, questionnaire answers, and prior imaging studies on muscle biopsies by respective physicians and clinics, and no prior confirmed molecular testing of disease. Since most of the 4656 patients are adults, in most cases parental sample was not available for segregation analysis, and hence this study is mostly proband related, albeit some segregation studies on some families was performed. For the Jain Foundation program patients clinically suspected of having LGMD were enrolled in the study with informed consent through an institutional review board protocol (IRB00075815) approved by Emory University with the help of Jain Foundation. The Jain Foundation developed the "Automated limb‐girdle muscular dystrophy diagnostic assistant" tool, popularly referred to as ALDA (<https://jain-foundation.org/alda/content/login-tool>) (<http://www.jain-foundation.org/lgmd-subtyping-diagnosis-tool>) where physicians fill up their respective patient clinical parameters which is helpful in clinical prediction of the LGMD subtype. ALDA includes prediction of all currently identified LGMD subtypes as well as other muscular dystrophies having similar clinical presentations.[25](#acn3649-bib-0025){ref-type="ref"} The ALDA tool results report out two main parameters, probability and concordance. Based on the provided patient clinical information by the physician, the probability percentage indicates up to the top three most likely clinical diagnoses for each patient. The concordance score represents how well the patient phenotype corresponds to the predicted LGMD subtypes, based on the available information in the published scientific literature. A subset of the patients with muscle phenotypes were initially screened using the online ALDA tool questionnaires and all positively screened LGMD patients by respective physicians were enrolled in the current large scale study. Additionally, patients, only in consultation with their respective clinics and physicians, could enter the study by answering the sequencing program website (<http://lgmd-diagnosis.org/>) (<https://www.jain-foundation.org/patient-physician-resources/free-genetic-sequencing>) questions that were stored as part of clinical data (See Questionnaires in [Supporting Information Methods](#acn3649-sup-0001){ref-type="supplementary-material"}). For the MDA program, neurologists from different MDA clinics across US also referred LGMD‐suspected patients for this large scale molecular testing program and also used the ALDA tool for providing us quantifiable clinical data.

During recruitment, ethnicity of patients was not one of the questions that we asked in our intake questionnaire. Although, in ALDA, we ask whether the patient was Finnish, Other Northern European, Japanese, other not listed, or unknown (see questionnaires in [Supporting Information Methods](#acn3649-sup-0001){ref-type="supplementary-material"}). The reason for these specific choices is because there are specific types of LGMDs that are more common in these ethnicities so that is important to take these into account when predicting the possible type of LGMDs.

For details of the patient questionnaires for recruitment to the sequencing program, see ([Supporting Information Methods](#acn3649-sup-0001){ref-type="supplementary-material"}).

Targeted gene panel testing {#acn3649-sec-0008}
---------------------------

Clinical NGS of targeted gene‐panel was performed at the Emory Genetics Laboratory (EGL), a facility certified by the Clinical Laboratory Improvement Amendments and College of American Pathologists (CLIA‐CAP) as previously described.[17](#acn3649-bib-0017){ref-type="ref"} Genomic DNA was isolated from peripheral blood samples or saliva samples for each patient referred for molecular testing. The list of potential LGMD genes to screen is too large for a single gene testing approach, but is very well suited for a targeted NGS panel. Genes selected for this panel were based on their evidence for disease causality, their relative contribution to disease as described in the literature[26](#acn3649-bib-0026){ref-type="ref"} and relative cost analysis. A total of 35 genes related to specific LGMD subtypes or other muscular dystrophies with clinical overlap with LGMD features were included in this NGS panel ([Table S2](#acn3649-sup-0001){ref-type="supplementary-material"}). Targeted NGS was performed as described by us previously[17](#acn3649-bib-0017){ref-type="ref"} with 100% coverage for each gene in the panel using Agilent SureSelect target enrichment. Patient genomic DNA was sheared to a 200 bp average, followed by end‐repair, A‐tailing, adapter ligation, and library amplification. Samples were then hybridized with the capture library. The probes were biotin tagged to allow for capture by streptavidin beads following hybridization. Prepared libraries were then indexed and amplified. Direct sequencing of the amplified captured regions was performed using next generation short base pair read sequencing. Although this assay was not designed to detect intragenic deletions and duplications, breakpoint bait was included in NGS library for common adult‐onset Pompe deletion of exon 18 and two intronic dysferlin pathogenic variants.

NGS data analysis and variant interpretation {#acn3649-sec-0009}
--------------------------------------------

We analyzed targeted NGS variant data, and identified variants classified according to board standards and guidelines[27](#acn3649-bib-0027){ref-type="ref"}, [28](#acn3649-bib-0028){ref-type="ref"} (<http://www.egl-eurofins.com/emvclass/emvclass.php>). Alignment to the human reference genome (hg19) and variant calling was performed using NextGENe^®^. For all 35 genes included in the panel ([Table S2](#acn3649-sup-0001){ref-type="supplementary-material"}), the analyzed region includes the coding exons and 10 bp of flanking intronic region on both sides of each exon. Certain known deep intronic variants were also targeted. We analyzed targeted NGS variant data carefully considering other important parameters such as available clinical phenotype information, family history and sequence result (if available) and previous undiagnosed diagnostic genetic test results. Identified variants were classified according to standards and guidelines of the American College of Medical Genetics and Genomics and classification were made available[27](#acn3649-bib-0027){ref-type="ref"}, [28](#acn3649-bib-0028){ref-type="ref"} (<http://www.egl-eurofins.com/emvclass/emvclass.php>). Diagnostic yield was calculated based on definitive diagnosis of patients harboring pathogenic variants in autosome‐recessive, ‐dominant, and X‐linked genes and patients with one pathogenic and one variant of uncertain significance (VUS) in the same LGMD gene. Prevalence of each identified LGMD subtype identified by our clinical NGS panel diagnostic program was established and compared. Major genes contributing to LGMD genes were identified from the patients with definitive molecular diagnosis having pathogenic variants in autosome‐recessive, ‐dominant, and X‐linked genes. Homozygosity was compared for different subtypes of LGMD and relatively common variants were identified in different LGMD‐associated genes.

Peripheral blood mononuclear cells (PBMC) assay for Dysferlin (DYSF) protein estimate {#acn3649-sec-0010}
-------------------------------------------------------------------------------------

Cases suspected of dysferlinopathy, as in LGMD2B or Miyoshi myopathy with *DYSF* (OMIM\# 603009) variant(s), were analyzed for DYSF protein expression using our established blood PBMC assay.[25](#acn3649-bib-0025){ref-type="ref"}, [29](#acn3649-bib-0029){ref-type="ref"}, [30](#acn3649-bib-0030){ref-type="ref"}

Results {#acn3649-sec-0011}
=======

Definitive molecular diagnosis and demographics {#acn3649-sec-0012}
-----------------------------------------------

Seventy percent of the patients enrolled in the study were over 18 years of age, and 30 percent were less than 18 years with patient mean age during participation was about 40 years equally distributed among the two genders (male: 50.6%, female: 49.4%). About half of the patients (2359/4656; 50.66%) were recruited through more than 150 MDA clinics across the US (<https://www.mda.org/>) and the remaining half (2297/4656; 49.33%) recruited through the Jain Foundation. Overall diagnostic yield was based on definitive diagnosis of 1003 patients harboring pathogenic variants in autosome‐recessive, ‐dominant, and X‐linked genes and 256 patients with one pathogenic and one VUS in the same recessive LGMD gene, totaling to 1259 diagnosed cases. Gene contribution percentages, that is, yield of each LGMD subtypes were based on the 1003 patients harboring pathogenic variants with definitive diagnosis. The diagnostic yield does not include the possible digenic/multigenic cases that harbor a single pathogenic variant in ≥2 genes. Critical analysis of this extensive molecular data confirmed molecular diagnosis for 27% (1259/4656 cases) of all the patients belonging to eleven different autosomal‐recessive LGMD subtypes associated with *DYSF*(OMIM\# 603009), *FKRP*(OMIM\# 606596), *GAA*(OMIM\# 606800), *SGCA*(OMIM\# 600119), *SGCB*(OMIM\# 600900), *SGCG*(OMIM\# 608896), *TRIM32*(OMIM\# 602290), *FKTN*(OMIM\# 607440), *ANO5*(OMIM\# 608662), *POMT2*(OMIM\# 607439)*,* and *ISPD*(OMIM\# 614631). However, no cases with a definitive diagnosis were identified for the four autosomal‐recessive LGMD subtypes associated with *POMT1*(OMIM\# 607423), *SGCD*(OMIM\# 601411), *DAG1*(OMIM\# 128239)*,* and *POMGNT1*(OMIM\# 606822). Majority of the patients have pathogenic variants in one of the following genes: *CAPN3* (OMIM\# 114240) 17% (175/1003 cases), *DYSF* (OMIM\# 603009) 16% (167/1003 cases), *FKRP* (OMIM\# 606596) 9% (87/1003 cases), and *ANO5* (OMIM\# 608662) 7% (72/1003 cases); indicating that these genes are likely the major contributors to LGMD phenotypes in the US population (Fig. [1](#acn3649-fig-0001){ref-type="fig"}A and [Fig. S2](#acn3649-sup-0001){ref-type="supplementary-material"}). Pathogenic variants were identified in dominant LGMD genes *DNAJB6*(OMIM\# 611332), *MYOT*(OMIM\# 604103), and *CAV3*(OMIM\# 601253)*,* but not in the *TNPO3*(OMIM\# 610032) gene. Pathogenic variants also occurred in 10 genes with both autosomal‐recessive and ‐dominant inheritance including *CAPN3*,*COL6A1*,*COL6A2*(OMIM\# 120240), *COL6A3*(OMIM\# 120240), *DES*(OMIM\# 125660), *GNE*(OMIM\# 603824), *LMNA*(OMIM\# 150330), *TCAP* OMIM\# 604488), and *TTN*(OMIM\# 188840). In 24% (1125/4656 cases) of the patients, we found no reportable variants which are true negative group in our targeted LGMD gene‐panel NGS. In the rest (49%; 2272/4656 cases) patients, we identified reportable variants but did not confirm molecular diagnosis such as the cases with one pathogenic variant in a recessive genes or cases with one or two VUSs in a gene, or cases with a single pathogenic variant or VUS in multiple genes. Seventy‐two percent of identified reportable variants are classified as VUS, and 23% of the variants are classified as pathogenic variants (Fig. [2](#acn3649-fig-0002){ref-type="fig"}). Patients had at least one VUS either in *DYSF*(90 patients), *CAPN3*(44 patients), or in any of the three collagen genes (246 patients) ([Table S7](#acn3649-sup-0001){ref-type="supplementary-material"}) without any reportable variant in other LGMD genes. Overall, 45% of patients were of "Northern European" origin except Finnish, 29% were "Other Not Listed", 20% were "Unknown", and the remaining 5% comprised of ethnic origins of Finnish, North Asia, South Asia, Hispanic, Native American, and African American. These data originated from self‐reported responses by the patients on the testing form (see [Supporting Information Methods](#acn3649-sup-0001){ref-type="supplementary-material"}).

![Major contributing LGMD genes. (A) Molecular diagnosis has been established in 27% of the patients. A majority of these patients had a pathogenic variant in one of the following genes *CAPN3* 17%(175/1003), *DYSF* 16%(167/1003), *FKRP* 9%(87/1003), and *ANO5* 7%(72/1003) indicating that these genes are likely the major contributors to LGMD phenotype. (B) Number of unique pathogenic variants identified. Numbers of identified pathogenic variants were compared among the major contributing LGMD genes to understand the allelic heterogeneity of these genes. *DYSF*,*CAPN3,* and *COL6A1* were identified with the most pathogenic variants including 133, 95 and 40, respectively, in each gene, indicating more allelic heterogeneity in these genes.](ACN3-5-1574-g001){#acn3649-fig-0001}

![Types of variants identified in the tested LGMD patients. Variants were classified according to standards and guidelines of the American College of Medical Genetics and Genomics. Around 23% of the identified variants are pathogenic. Around 72% of the variants are interpreted as variants of uncertain significance (VUS) because majority of LGMD subtypes are poorly studied and currently limited knowledge available.](ACN3-5-1574-g002){#acn3649-fig-0002}

Allelic heterogeneity of major LGMD contributing genes {#acn3649-sec-0013}
------------------------------------------------------

We identified 133 unique pathogenic variants in the *DYSF* gene followed by 95 pathogenic variants in *CAPN3* and 40 pathogenic variants in *COL6A1* (OMIM\# 120220) thus indicating a high allelic heterogeneity in these genes (Figs. [1](#acn3649-fig-0001){ref-type="fig"}B and [2](#acn3649-fig-0002){ref-type="fig"}). This large‐scale study confirmed calpainopathy as the most common LGMD subtype (*CAPN3*‐associated LGMD2A: 175/1003 cases; 17%) in the USA. Sixteen percent of patients (167/1003 cases) had a definitive diagnosis of LGMD2B by identifying two pathogenic variants in the *DYSF* gene indicating LGMD2B is the second major contributor among the LGMD subtypes (Fig. [1](#acn3649-fig-0001){ref-type="fig"}A). Splice site pathogenic variant c.2643 + 1G\>A was identified in 20 LGMD2B patients making it as the most common *DYSF* pathogenic variant followed by c.5713C\>T (p.R1905X) and c.5979dupA, as the second most common variants each found 12 patients.[31](#acn3649-bib-0031){ref-type="ref"} Extensive homozygosity of variants was observed in the *DYSF* (10%), *FKRP* (7%), and *CAPN3* (6%) genes (Fig. [3](#acn3649-fig-0003){ref-type="fig"}).

![Homozygosity identified in major LGMD genes. Percentage of homozygous pathogenic variants identified in major LGMD genes.](ACN3-5-1574-g003){#acn3649-fig-0003}

Mode of inheritance in LGMD subtypes {#acn3649-sec-0014}
------------------------------------

In addition to being the most common LGMD subtype (*CAPN3*‐associated LGMD2A: 17%), we report that 17 unrelated patients with a 21 bp in‐frame deletion (c.643_663del21) in *CAPN3* gene who did not possess a second reportable variant (Table 2). This variant occurred in multiple different families with muscle disease, segregating with dominant inheritance.[32](#acn3649-bib-0032){ref-type="ref"}, [33](#acn3649-bib-0033){ref-type="ref"}, [34](#acn3649-bib-0034){ref-type="ref"} A second 15 bp in‐frame deletion (c.598_612del15) was also identified in different 16 unrelated patients. Most of these 16 patients had no identified second variant, indicating an increased prevalence of autosomal‐dominant *CAPN3‐*associated LGMD subtype (Table 2).

Prevalence of late‐onset Pompe in large LGMD‐suspected cohort {#acn3649-sec-0015}
-------------------------------------------------------------

We identified 28 LGMD‐suspected patients, all with two *GAA* pathogenic variants (Table [1](#acn3649-tbl-0001){ref-type="table"}). We also identified 10 patients with one pathogenic variant and one VUS in *GAA* which is likely to be pathogenic given no other mutation in *GAA* or other genes and that the patients show clinical symptoms ([Table S3](#acn3649-sup-0001){ref-type="supplementary-material"}), totaling to 38 identified late‐onset Pompe cases (38/4656; 0.8% prevalence). It is interesting to note that none of the patients had homozygous variants in *GAA* (Table [1](#acn3649-tbl-0001){ref-type="table"}) with the c.‐32‐13T\>G leaky splice variant identified in 31 of 38 LOPD patients in the compound‐heterozygous state. The common exon‐18 deletion (c.2481 + 102_2646 + 31del) was found in five patients along with the leaky‐splice variant. The third common variant, c.525delT, was identified in five LOPD patients. Ninety‐one patients had at least one pathogenic variant in *GAA* indicating further deletion, duplication, and enzymatic analysis are warranted in these individuals.

###### 

Summary of *GAA* variants identified in late‐onset Pompe patients. Identification of 28 patients with two *GAA* pathogenic variants indicates the increased prevalence of late‐onset Pompe disease in this study. (AOP: Adult‐onset Pompe)

  Patient ID   Gender    Age   Gene    Variant 1            Variant 2
  ------------ --------- ----- ------- -------------------- ----------------------------------------------
  AOP1         Female    61    *GAA*   c.‐32‐13T\>G         c.1124G\>T (p.R375L)
  AOP2         Female    79    *GAA*   c.‐32‐13T\>G         c.2140delC
  AOP3         Female    33    *GAA*   c.‐32‐13T\>G         c.525delT
  AOP4         Male      71    *GAA*   c.‐32‐13T\>G         c.1912G\>T (p.G638W)
  AOP5         Unknown   54    *GAA*   c.‐32‐13T\>G         c.2512C\>T(p.Q838X)
  AOP6         Male      66    *GAA*   c.‐32‐13T\>G         c.2481 + 102_2646 + 31del (Exon 18 deletion)
  AOP7         Male      70    *GAA*   c.‐32‐13T\>G         c.2481 + 102_2646 + 31del (Exon 18 deletion)
  AOP8         Female    44    *GAA*   c.‐32‐13T\>G         c.2481 + 102_2646 + 31del (Exon 18 deletion)
  AOP9         Male      18    *GAA*   c.‐32‐13T\>G         c.2481 + 102_2646 + 31del (Exon 18 deletion)
  AOP10        Male      40    *GAA*   c.‐32‐13T\>G         c.2238G\>A(p.W746X)
  AOP11        Male      59    *GAA*   c.‐32‐13T\>G         c.1655T\>C(p.L552P)
  AOP12        Male      70    *GAA*   c.736delC            c.546G\>A(p.T183T)
  AOP13        Female    53    *GAA*   c.‐32‐13T\>G         c.1841C\>A(p.T614K)
  AOP14        Male      68    *GAA*   c.‐32‐13T\>G         c.1143delC
  AOP15        Female    40    *GAA*   c.853C\>T(p.P285S)   c.2560C\>T(p.R854X)
  AOP16        Male      41    *GAA*   c.‐32‐13T\>G         c.2560C\>T(p.R854X)
  AOP17        Male      44    *GAA*   c.‐32‐13T\>G         c.655G\>A(p.G219R)
  AOP18        Male      70    *GAA*   c.‐32‐13T\>G         c.1064T\>C(p.L355P)
  AOP19        Female    49    *GAA*   c.‐32‐13T\>G         c.1655T\>C(p.L552P)
  AOP20        Female    56    *GAA*   c.‐32‐13T\>G         c.525delT
  AOP21        Female    36    *GAA*   c.‐32‐13T\>G         c.1827delC
  AOP22        Male      80    *GAA*   c.‐32‐13T\>G         c.525delT
  AOP23        Male      33    *GAA*   c.‐32‐13T\>G         c.258dupC
  AOP24        Female    46    *GAA*   c.‐32‐13T\>G         c.766_785delTATATCACAGGCCTCGCCGAinsC
  AOP25        Female    61    *GAA*   c.‐32‐13T\>G         c.2481 + 102_2646 + 31del (Exon 18 deletion)
  AOP26        Male      18    *GAA*   c.‐32‐13T\>G         c.525delT
  AOP27        Female    56    *GAA*   c.‐32‐13T\>G         c.525delT
  AOP28        Female    8     *GAA*   c.‐32‐13T\>G         c.2242dupG

John Wiley & Sons, Ltd

*DNAJB6‐*associated LGMD subtype 1E molecular diagnosis and prevalence {#acn3649-sec-0016}
----------------------------------------------------------------------

*DNAJB6* (OMIM\# 611332) is an autosomal‐dominant gene associated with limb‐girdle muscular dystrophy 1E (LGMD1E). We identified 29 LGMD1E cases with pathogenic variants and 13 additional cases with novel missense variants in *DNAJB6* (OMIM\# 611332) gene. *MYOT* (OMIM\# 604103) was the next major contributor to the autosomal‐dominant LGMD group with pathogenic variants identified in 30 patients.

Multigenic inheritance in muscular dystrophy {#acn3649-sec-0017}
--------------------------------------------

Instead of one locus, alterations in two genes are required for phenotypic expression in digenic inheritance as in retinitis pigmentosa (*ROM1* (OMIM\# 180721) and *PRPH2* (OMIM\# 179605)), as well as in different muscular dystrophies such as Emery‐Dreifuss, limb‐girdle, Ullrich congenital and facioscapulohumeral,[35](#acn3649-bib-0035){ref-type="ref"}, [36](#acn3649-bib-0036){ref-type="ref"}, [37](#acn3649-bib-0037){ref-type="ref"}, [38](#acn3649-bib-0038){ref-type="ref"} indicating more complex nature of disease presentation and progression in muscular disorders.[35](#acn3649-bib-0035){ref-type="ref"}, [36](#acn3649-bib-0036){ref-type="ref"}, [37](#acn3649-bib-0037){ref-type="ref"}, [38](#acn3649-bib-0038){ref-type="ref"} Our data identified pathogenic variants in more than one LGMD genes in at least 31 individuals suggesting potential digenic or multiple genes contribution to LGMD disease presentation and progression (Fig. [4](#acn3649-fig-0004){ref-type="fig"} and Table S1). Majority of these patients showed atypical clinical presentation and in some cases unusually rapid or very slow progression (Table S1). For example, a 32‐year‐old Caucasian male patient had initial symptoms in his late teens including onset of muscle weakness in arms and legs as well as elevated CK levels was diagnosed with LGMD, but unusual, rapid progression of proximal leg and girdle weakness occurred. Two homozygous variants in two muscle genes *ANO5* and *SGCA* (Fig. [4](#acn3649-fig-0004){ref-type="fig"}; Table S1) could be potentially contributing to the unusual presentation in this individual. A 16‐year‐old male clinically diagnosed with LGMD, but with an unexpected severe progression had heterozygous loss of *COL6A2* coupled with a homozygous loss of *ANO5* possibly contributing to the rapid disease progression and severe phenotype (Fig. [4](#acn3649-fig-0004){ref-type="fig"}; Table S1). In this family, the 40‐year‐old mother with heterozygous loss of both *ANO5* and *COL6A2* showed mild myopathy, whereas her 8‐year‐old daughter with the same genotype had no muscle weakness indicating variable presentation and the possibility of later‐onset clinical features. There are multiple other patient cases identified with single pathogenic variant in one recessive gene and another single VUS in a different recessive gene with no other reportable variant.

![Multigenic inheritance in LGMD. Pathogenic variants identified in more than one LGMD genes in two patients with unusual disease presentation and progression indicating complex inheritance patterns of LGMD. (A) Patient with homozygous variants in both *ANO5* and *SGCA* genes. NGS reads indicated the identification of homozygous missense pathogenic variants c.2272C\>T (p.R758C) and c.850C\>T (R284C) in *ANO5* and *SGCA* genes, respectively. (B) Rapid disease progression was observed in a 16‐year‐old male (arrow) with two pathogenic variants in *ANO5* gene and one pathogenic variant in *COL6A2* gene indicating multiple gene contributions for an unusual presentation. His mother, a 40‐year‐old female with one pathogenic variant each in *ANO5* and *COL6A2* shows unspecified myopathy with elevated creatine phosphokinase (CPK).](ACN3-5-1574-g004){#acn3649-fig-0004}

Deep intronic variant in *DYSF* gene {#acn3649-sec-0018}
------------------------------------

Recently, we characterized a deep intronic mRNA splice‐altering pathogenic variant c.4886 + 1249G\>T in *DYSF* gene that inserts a novel 177 bp pseudoexon at the exon 44--45 junction. This splicing causes an in‐frame insertion of 59 additional amino acids in the dysferlin protein.[39](#acn3649-bib-0039){ref-type="ref"} This intronic variant segregated in a compound heterozygous state with the other pathogenic variant in two siblings (Fig. [5](#acn3649-fig-0005){ref-type="fig"}). Dysferlin protein expression levels in PBMC showed an evident pathogenic effect of the deep intronic splice variant in significantly reducing DYSF expression in the compound heterozygous states (Fig. [5](#acn3649-fig-0005){ref-type="fig"}).We targeted this deep intronic region in the current LGMD NGS panel and successfully identified it in one family. Overall we have been able to identify 45 different deep intronic variants including pathogenic or VUS across nine genes in our panel (*DMD*,*CAPN3*,*DNAJB6*,*GAA*,*DYSF*,*FKTN*,*COL6A1*,*COL6A2*,*COL6A3*) in all different unrelated patients in our cohort (additionally see [Tables S3--S7](#acn3649-sup-0001){ref-type="supplementary-material"}).

![Segregation analysis of a deep intronic *DYSF* variant. Variant c.4886 + 1249G\>T in *DYSF* gene was identified in a large family with LGMD2B. A deep intronic variant in *DYSF* gene alters mRNA splicing and ultimately results in inframe insertion of a new pseudoexon in dysferlin. Percentages indicate levels of expression of dysferlin protein in peripheral blood mononuclear cells (PBMCs) compared to the control.](ACN3-5-1574-g005){#acn3649-fig-0005}

Collagen family genes {#acn3649-sec-0019}
---------------------

Collagen family genes *COL6A1/A2/A3* are associated with both autosomal‐dominant and ‐recessive forms of muscular dystrophies. Variants located in the Gly‐X‐Y domain‐encoding region of these genes are associated with dominant forms of myopathy. Here we report 55 patients with pathogenic variants in the Gly‐X‐Y domain of these three genes; *COL6A1* is the major contributor with 35 patients. Eleven patients harbored two pathogenic variants in one of these genes, with eight patients having two pathogenic variants in *COL6A2* indicating a role in recessive myopathy. Seventy‐nine patients were identified with one pathogenic variant in any of these three genes ([Table S5](#acn3649-sup-0001){ref-type="supplementary-material"}).

Discussion {#acn3649-sec-0020}
==========

The severity of the different LGMD subtypes varies with most of the dominant forms having later‐onset ages and milder‐clinical presentations than the recessive subtypes.[40](#acn3649-bib-0040){ref-type="ref"} A large number of affected patients remain without a definitive molecular diagnosis regardless of \>30 LGMD genes are known, because of the current challenges of interpreting variants such as deep‐intronic or regulatory variants in known genes, or novel yet‐to‐be implicated genes. Most of the LGMD subtypes are genetically poorly studied, and limited knowledge is available regarding the mutation spectrum of different LGMD genes. This clinical‐diagnostic program provided a valuable opportunity to gain a deeper understanding of rare LGMD subtypes by studying 4656 patients throughout the USA. Moreover, since majority of these patients had the adult‐onset disease, our study adds to the knowledge base for use in newborn‐genetic‐screening programs that will enable earlier intervention if available. Major contributors to LGMD phenotypes were found to be *CAPN3*(17%), *DYSF*(16%), *FKRP*(9%), and *ANO5*(7%) (Fig. [1](#acn3649-fig-0001){ref-type="fig"}A). No reportable variants were identified in 24% patients indicating a possible role of deep‐intronic/regulatory‐variants/novel genes.

Our LGMD panel diagnostic yield (27%) is smaller than that of our previous NMD panel (46%) since previously yield was for all NMDs, not just for LGMD, and the cohort was much smaller (81 patients).[17](#acn3649-bib-0017){ref-type="ref"} Identification of pathogenic variants in dominant LGMD genes *DNAJB6*,*MYOT*, and *CAV3,* but not in the *TNPO3* gene indicates a higher prevalence of dominant LGMD‐subtypes‐1E,1A,1C, respectively, and the rarity of LGMD‐1F. The 27% diagnostic yield included the 256 patients with one pathogenic and one VUS in the same LGMD gene since it is most likely these VUSs are likely pathogenic as the patients show clinical symptoms and no other variant was identified in the same or any other gene. The diagnostic yield of our study is slightly higher than some previous exome sequencing studies in neurological disorders, even with a substantial patient cohort recruited based on specific disease phenotypes.[41](#acn3649-bib-0041){ref-type="ref"}, [42](#acn3649-bib-0042){ref-type="ref"} This suggests the importance of using screening criteria of disease‐specific clinical information carefully to judge the type of NGS‐diagnostic testing for patient recruitment (fig. [3](#acn3649-fig-0003){ref-type="fig"} in [43](#acn3649-bib-0043){ref-type="ref"}) and justifying subsequent advantage of targeted NGS panel over exome sequencing.

Due to overlapping phenotypes and complex presentations, it is difficult for clinicians to provide an accurate clinical diagnosis especially for Duchenne/Becker muscular dystrophy (DMD/BMD) patients with milder presentations, which often mimics limb‐girdle phenotypes. Unlike some well‐known LGMD gene panels from popular commercial diagnostic clinics, we included common X‐linked muscular dystrophy genes *DMD*(OMIM\# 300377), *EMD*(OMIM\# 300384), *FHL1*(OMIM\# 300163) in the NGS LGMD‐panel, and 43 patients were identified with pathogenic variants in *DMD*. Also, the complete lack of coverage for consecutive exons in the *DMD* gene was also observed in 10 patients indicating possible pathogenic deletions. These pathogentic deletions stress the importance of comprehensive clinical evaluation for DMD/BMD patients with a milder‐presentation before referring to NGS‐panel testing for other muscular dystrophies.[43](#acn3649-bib-0043){ref-type="ref"}

Dysferlinopathies (LGMD2B and Miyoshi myopathy) include autosomal‐recessive muscle diseases caused by pathogenic variants in dysferlin gene (*DYSF*), characterized by proximal muscle weakness, difficulty in running, climbing, increased fatigue.[44](#acn3649-bib-0044){ref-type="ref"}, [45](#acn3649-bib-0045){ref-type="ref"} *DYSF*,*CAPN3,* and *COL6A1* have the highest number of pathogenic variants indicating more allelic heterogeneity in these genes compared to others in the panel (Fig. [1](#acn3649-fig-0001){ref-type="fig"}B). Comparing Figure [1](#acn3649-fig-0001){ref-type="fig"}A and B, it is seen that *FKRP*, the third most contributing gene (Fig. [1](#acn3649-fig-0001){ref-type="fig"}A), has low allelic heterogeneity (lesser number of unique pathogenic variants), whereas *TTN* harbors high number of unique pathogenic variants (higher allelic heterogeneity) (Fig. [1](#acn3649-fig-0001){ref-type="fig"}B) even though being one of the least‐contributing genes. This indicates that even greater number of unique pathogenic variants such as deep‐intronic/deletion/duplications could potentially be identified in *TTN* with confirmed LGMD2J diagnosis, if we use whole genome sequencing instead of panel testing. These indicate therefore, LGMD overall might still remain clinically under diagnosed. Moreover, extensive homozygosity of variants in *DYSF*,*FKRP,* and *CAPN3* genes highlights the immediate need for carrier testing for these LGMD subtypes (Fig. [3](#acn3649-fig-0003){ref-type="fig"}). The 79 patients identified with one pathogenic variant in any of the three collagen genes ([Table S5](#acn3649-sup-0001){ref-type="supplementary-material"}) may not be of diagnostic value since *COL6A1/A2/A3* variants can be either recessive/dominant, depending on the individual\'s family history. Hence further functional studies using target muscle biopsy tissue, segregation analysis and nature history studies are needed for those patients with one pathogenic variant in a collagen gene.

Late‐onset Pompe disease (LOPD) is a rare, but potentially treatable lysosomal storage disorder characterized by progressive glycogen accumulation and muscle weakness, often with a limb‐girdle pattern of weakness. It is essential that such patients should not be overlooked. Increased prevalence (2.4--3.63%) in LOPD was observed previously in LGMD‐suspected or hyperCKemia patients using targeted sequencing approach.[46](#acn3649-bib-0046){ref-type="ref"}, [47](#acn3649-bib-0047){ref-type="ref"}, [48](#acn3649-bib-0048){ref-type="ref"} But these studies are different with regard to much lower number of patient cohort that unlike our study also included non‐LGMD other NMD patients such as other congenital myopathies, distal myopathies, and isolated hyperCKemia in European population. Our results of prevalence of LOPD through targeted LGMD gene‐panel testing in a very large strictly clinically LGMD‐characterized or ‐suspected patients across US with multiple ethnicities indicate that LOPD should not be overlooked when considering potential diagnoses for LGMD patients even if clinical subtyping can be performed, that in turn will assist in ERT or recruitment for other clinical trials.

This large‐scale study confirmed that LGMD2A (calpainopathy), characterized by severe‐to‐mild, symmetric, progressive weakness of proximal limb‐girdle muscles with 2--40 years onset‐age, as the most common LGMD subtype with the higher prevalence of dominant LGMD forms. LGMD2A was considered a strictly autosomal‐recessive‐LGMD subtype for many years, but recently patients carrying a single pathogenic variant in the *CAPN3* have been reported. This variant, a 21 bp in‐frame deletion c.643_663del21, cosegregates in 37 individuals from 10 families with muscle disease and dominant‐transmission through several generations. Moreover, it is associated with severe loss of calpain3 expression shown by immunoblotting, suggesting a dominant‐negative effect on calpain3 homodimer.[33](#acn3649-bib-0033){ref-type="ref"} In our large‐scale study, the identification of the same 21 bp in‐frame deletion in 17 individuals (Table [2](#acn3649-tbl-0002){ref-type="table"}) without any reportable second variant further confirms the c.643_663del21 as a common, dominant mutation, but further deletion‐duplication analysis did not occur. Even *CAPN3* inheritance is considered only autosomal recessive in OMIM (<https://www.omim.org/entry/114240>). Hence it is important to emphasize that through our very large sequencing program, we now know that dominant inheritance of *CAPN3* is far more prevalent than previously thought, and should be widely considered in molecular diagnostic pipeline and NGS data analysis and interpretation in the clinics. Our finding of a similar 15 bp in‐frame deletion c.598_612del15 in 16 patients with ages ranging from 48 to 76 years (Table [2](#acn3649-tbl-0002){ref-type="table"}) without a second pathogenic variant indicate a possible autosomal‐dominant form of calpainopathy. The same 15 bp in‐frame deletion c.598_612del15 as a single *CAPN3* variant was previously described in one patient, but dominant inheritance was not suggested.[49](#acn3649-bib-0049){ref-type="ref"}, [50](#acn3649-bib-0050){ref-type="ref"} Further studies are required to confirm the dominant subtype associated with this *CAPN3* variant.

###### 

*CAPN3* patients with in‐frame deletions associated with autosomal‐dominant subtype

  Patient ID   Gender   Age (years)   *CAPN3* variant 1   *CAPN3* variant 2
  ------------ -------- ------------- ------------------- ---------------------------
  C100         Male     24            c.643_663del21      ---
  C200         Male     72            c.643_663del21      ---
  C300         Male     44            c.643_663del21      ---
  C400         Female   70            c.643_663del21      ---
  C500         Male     58            c.643_663del21      c.584A\>C (p.N195T), VUS
  C600         Female   73            c.643_663del21      ---
  C700         Male     57            c.643_663del21      ---
  C800         Male     60            c.643_663del21      ---
  C900         Female   61            c.643_663del21      ---
  C111         Male     69            c.643_663del21      ---
  C222         Female   17            c.643_663del21      ---
  C333         Male     57            c.643_663del21      c.640G\>A (p.G214S), VUS
  C444         Female   34            c.643_663del21      ---
  C555         Male     45            c.643_663del21      ---
  C666         Female   13            c.643_663del21      ---
  C777         Female   78            c.643_663del21      ---
  C888         Female   73            c.643_663del21      ---
  D001         Male     59            c.598_612del15      ---
  D002         Female   57            c.598_612del15      ---
  D003         Female   48            c.598_612del15      ---
  D004         Male     69            c.598_612del15      ---
  D005         Female   59            c.598_612del15      ---
  D006         Male     57            c.598_612del15      c.794C\>T (p.S265F), VUS
  D007         Female   58            c.598_612del15      c.1477C\>T (p.R493W), VUS
  D008         Female   54            c.598_612del15      ---
  D009         Female   57            c.598_612del15      ---
  D010         Male     76            c.598_612del15      ---
  D011         Female   53            c.598_612del15      c.1505T\>C (p.I502T), VUS
  D012         Female   54            c.598_612del15      ---
  D013         Male     39            c.598_612del15      ---
  D014         Female   59            c.598_612del15      ---
  D015         Female   69            c.598_612del15      ---
  D016         Male     66            c.598_612del15      ---

VUS, Variant of uncertain significance.
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Another interesting dominant LGMD subtype identified is the poorly studied *DNAJB6*‐associated‐LGMD1E, which is a mostly adult‐onset, slowly progressive proximal muscle‐weakness. Nevertheless, some early onset cases were reported.[51](#acn3649-bib-0051){ref-type="ref"}, [52](#acn3649-bib-0052){ref-type="ref"} *DNAJB6* encodes a protein that belongs to DNAJ family, a class of molecular chaperones, involved in a wide range of cellular events.[53](#acn3649-bib-0053){ref-type="ref"}, [54](#acn3649-bib-0054){ref-type="ref"} The mutation spectrum for *DNAJB6* is limited to 11 missense variants and one splice variant ([Table S6](#acn3649-sup-0001){ref-type="supplementary-material"}) with most of them located in the mutational‐hotspot region of exon‐5 in the G/F‐rich linker domain.[54](#acn3649-bib-0054){ref-type="ref"} Only one reported variant c.525C\>G(p.F175L) is located in exon‐7 and no nonsense/frameshift variants have been reported. We report 29 patients with pathogenic missense variants in the exon‐5 hotspot; but also identified 13 patients with novel missense variants outside of exon‐5 (exons 4, 6, 7, 8, 9, 10) of *DNAJB6* ([Table S4](#acn3649-sup-0001){ref-type="supplementary-material"}) with no other reportable variants in an LGMD gene. These data indicate a broad mutation spectrum for *DNAJB6* and a need for natural‐history studies to understand the penetrance and nature of disease association. These 13 missense variants are further classified as VUS due to lack of published studies on LGMD1E and signifies the need for functional validation for reclassification of the VUSs and natural history studies on these patients to determine nature of variant contribution to disease.

Our targeted NGS panel data identified at least 31 individuals with pathogenic variants in more than one LGMD gene suggesting potential digenic/multiple gene contributions to LGMD disease presentation/progression (Fig. [4](#acn3649-fig-0004){ref-type="fig"}; Table S1). The explicit possible association of multigenic pathogenicity to unusual disease presentation with rapid/very slow progression seen in all 31 cases (Table S1) in our cohort including examples given in above ([Results](#acn3649-sec-0011){ref-type="sec"}), suggests a potential high prevalence of gene‐gene epistatic interaction and synergistic heterozygosity[55](#acn3649-bib-0055){ref-type="ref"} in LGMD. Albeit, further functional and segregation studies are needed to validate the complex inheritance patterns of LGMD subtypes.[55](#acn3649-bib-0055){ref-type="ref"} Moreover, we expect whole genome sequencing is needed on these patients to confirm if there are any other reportable pathogenic variant that could definitively diagnose these patients, before performing functional and segregation studies on them to understand multigenic contribution.

The findings that 72% identified reportable variants are classified as VUSs, and 23% of the variants are classified as pathogenic variants indicate the importance of further functional studies including RNA sequencing, enzyme assays or mass spectrometry to prove pathogenicity of identified VUSs.[56](#acn3649-bib-0056){ref-type="ref"}, [57](#acn3649-bib-0057){ref-type="ref"} This will further aid in resolving the diagnosis of patients with at least one VUS either in *DYSF* or *CAPN3* or any of the three collagen genes ([Table S7](#acn3649-sup-0001){ref-type="supplementary-material"}).

Overall, the current large‐scale LGMD sequencing project has improved our knowledge of the gene‐variant spectrum, mutational hotspots, genetic etiologies, and relative prevalence of different LGMD subtypes across the US using a large clinically characterized patient cohort, allowing timely management, participation of definitively diagnosed individuals in ongoing clinical trials through disease‐specific registries. This large US‐cohort not previously described for LGMD has also showed evidence for a new mechanism which has been previously described in handful of cases in the literature. We identified the higher prevalence of dominant forms of LGMD, *CAPN3,* and *DNAJB6* in particular and novel digenic/multigenic (more than 2) possible contribution to unusual LGMD clinical presentations/progressions. Adult‐onset Pompe patients, also identified in our LGMD‐suspected cohort, now have the opportunity of seeking enzyme replacement therapy. The slightly higher diagnostic yield of this study compared to our previous exome studies on NMD patients and exomes of neurological disorders in general as mentioned before, as well as the identification of 24% negative cases suggests yet‐to‐be discovered genes or genetic events associated with LGMD‐like clinical symptoms. To resolve these cases, we predict the need for clinical genome sequencing (GS) to capture the full genetic variation spectrum as seen in recent trends in large clinical diagnostics studies as a first‐tier approach.[58](#acn3649-bib-0058){ref-type="ref"} We expect a shift from panel sequencing to clinical‐GS with better, uniform coverage therefore leading fewer exon drop‐out, to detect deep‐intronic and copy‐number variants, and ability to interrogate periodically without resequencing.
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**Methods.** Questionnaires for patient recruitment.**Figure S1.** Pictorial representation of different muscle‐related proteins associated with various subtypes of LGMD is shown here pictorially in an interlinked chemomechanical network of sarcomere, sarcoplasm, sarcolemma, and extracellular matrix.

**Figure S2.** Contribution of different LGMD genes. Molecular diagnosis has been established in 27% of the patients with the majority having pathogenic variants identified in one of the following genes *CAPN3* (17%), *DYSF* (16%), *FKRP* (9%), and ANO5 (7%) indicating that these genes are likely the major contributors to LGMD like phenotype.

**Table S1.** Summarized list of some of the affected cases with pathogenic variants in multiple genes and unusual clinical presentations.

**Table S2.** List of genes in the targeted LGMD panel testing with their respective LGMD subtype or other associated neuromuscular disease with/without overlapping LGMD subtype.

**Table S3.** Summary of late onset patients with one pathogenic variant and one variant of uncertain significance in the *GAA* gene.

**Table S4.** Summary of patients with *DNAJB6* variants.

**Table S5.** List of patients with pathogenic variants in *COL6A1*,*COL6A2,* and *COL6A3* genes.

**Table S6.** Mutation spectrum of *DNAJB6* gene. List of variants reported in the Human Gene Mutation Database (HGMD).

**Table S7.** List of variants of uncertain significance (VUS) identified in major LGMD genes.
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Click here for additional data file.
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